HealthEquity (NASDAQ:HQY) Releases FY 2026 Earnings Guidance

Key Points

• HealthEquity has issued FY 2026 earnings guidance with an expected earnings per share (EPS) range of 3.740-3.91, surpassing the consensus estimate of 3.480.
• The company projects revenue of $1.3 billion, consistent with market expectations, while its shares recently traded at $88.85 after a drop of $0.48.
• HealthEquity has received positive ratings from analysts, with upgrades to "buy" and target prices ranging from $104.00 to $125.00, indicating bullish sentiment towards the stock.

HealthEquity (NASDAQ:HQY - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.740-3.91 for the period, compared to the consensus estimate of 3.480. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

HealthEquity Price Performance

Shares of NASDAQ HQY traded down $0.48 during midday trading on Tuesday, hitting $88.85. The company had a trading volume of 2,773,945 shares, compared to its average volume of 1,020,289. The company has a quick ratio of 4.06, a current ratio of 4.06 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of 64.85, a price-to-earnings-growth ratio of 1.38 and a beta of 0.50. The business has a 50-day simple moving average of $95.26 and a two-hundred day simple moving average of $95.41. HealthEquity has a twelve month low of $73.84 and a twelve month high of $116.65.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, September 2nd. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. Equities research analysts anticipate that HealthEquity will post 2.32 earnings per share for the current year.

Analysts Set New Price Targets

HQY has been the subject of a number of research reports. Wall Street Zen upgraded shares of HealthEquity from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. JMP Securities lifted their target price on shares of HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research report on Wednesday, June 4th. Barrington Research restated an "outperform" rating and set a $125.00 target price on shares of HealthEquity in a research report on Friday. The Goldman Sachs Group lifted their target price on shares of HealthEquity from $94.00 to $104.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 4th. Finally, Raymond James Financial restated a "strong-buy" rating and set a $120.00 target price (up previously from $115.00) on shares of HealthEquity in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $117.82.

Insider Activity at HealthEquity

In related news, EVP Michael Henry Fiore sold 1,794 shares of the business's stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $101.73, for a total value of $182,503.62. Following the completion of the sale, the executive vice president directly owned 53,225 shares in the company, valued at approximately $5,414,579.25. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jon Kessler sold 97,767 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $112.05, for a total transaction of $10,954,792.35. Following the completion of the sale, the director owned 75,000 shares of the company's stock, valued at approximately $8,403,750. The trade was a 56.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 291,744 shares of company stock worth $32,705,007. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On HealthEquity

Institutional investors have recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. purchased a new stake in HealthEquity during the second quarter worth approximately $217,000. B. Riley Wealth Advisors Inc. purchased a new stake in HealthEquity during the second quarter worth approximately $273,000. Orion Porfolio Solutions LLC grew its stake in HealthEquity by 14.9% during the second quarter. Orion Porfolio Solutions LLC now owns 3,770 shares of the company's stock worth $395,000 after buying an additional 490 shares during the period. Jump Financial LLC purchased a new stake in HealthEquity during the second quarter worth approximately $449,000. Finally, Corient Private Wealth LLC purchased a new stake in HealthEquity during the second quarter worth approximately $518,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.